Literature DB >> 29063589

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

A S Felix1, T M Brasky2, D E Cohn3, D G Mutch4, W T Creasman5, P H Thaker4, J L Walker6, R G Moore7, S B Lele8, S R Guntupalli9, L S Downs10, Ci Nagel11, J F Boggess12, M L Pearl13, O B Ioffe14, W Deng8, D S Miller15, L A Brinton16.   

Abstract

Non-Hispanic black (NHB) women are more likely to experience an endometrial carcinoma (EC) recurrence compared to non-Hispanic white (NHW) women. The extent to which tumor characteristics, socioeconomic status (SES) and treatment contribute to this observation is not well defined. In the NRG Oncology/Gynecology Oncology Group (GOG) 210 Study we evaluated associations between race/ethnicity and EC recurrence according to tumor characteristics with adjustment for potential confounders. Our analysis included 3,199 NHW, 532 NHB and 232 Hispanic women with EC. Recurrence was documented during follow-up. We used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between race/ethnicity and EC recurrence in models stratified by histologic subtype (low-grade endometrioid, high-grade endometrioid, serous, mixed cell, carcinosarcoma, clear cell) or stage (I, II, III) and adjusted for age, SES, body mass index, smoking status and treatment. In histologic subtype-stratified models, higher EC recurrence was noted in NHB women with low-grade endometrioid (HR = 1.94, 95% CI = 1.21-3.10) or carcinosarcomas (HR = 1.66, 95% CI = 0.99-2.79) compared to NHWs. In stage-stratified models, higher EC recurrence was noted among NHB women with stage I (HR = 1.48, 95% CI = 1.06-2.05) and Hispanic women with stage III disease (HR = 1.81, 95% CI = 1.11-2.95). Our observations of higher EC recurrence risk among NHB and Hispanic women, as compared to NHW women, were not explained by tumor characteristics, SES, treatment or other confounders. Other factors, such as racial differences in tumor biology or other patient factors, should be explored as contributors to racial disparities in EC recurrence.
© 2017 UICC.

Entities:  

Keywords:  outcomes; racial disparities; socioeconomic status; tumor heterogeneity; uterus neoplasm

Mesh:

Year:  2017        PMID: 29063589      PMCID: PMC5798245          DOI: 10.1002/ijc.31127

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.

Authors:  Emily M Ko; Paige Walter; Leslie Clark; Amanda Jackson; Jason Franasiak; Corey Bolac; Laura Havrilesky; Angeles Alvarez Secord; Dominic T Moore; Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2014-04       Impact factor: 5.482

2.  Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.

Authors:  G L Maxwell; J I Risinger; K A Hayes; A A Alvarez; R K Dodge; J C Barrett; A Berchuck
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

3.  An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.

Authors:  Ritu Salani; Namita Khanna; Marina Frimer; Robert E Bristow; Lee-May Chen
Journal:  Gynecol Oncol       Date:  2017-03-31       Impact factor: 5.482

4.  Molecular profiling of endometrial cancers from African-American and Caucasian women.

Authors:  Sarah E Ferguson; Adam B Olshen; Douglas A Levine; Agnès Viale; Richard R Barakat; Jeff Boyd
Journal:  Gynecol Oncol       Date:  2005-12-27       Impact factor: 5.482

5.  p53 overexpression in advanced-stage endometrial adenocarcinoma.

Authors:  M F Kohler; P Carney; R Dodge; J T Soper; D L Clarke-Pearson; J R Marks; A Berchuck
Journal:  Am J Obstet Gynecol       Date:  1996-11       Impact factor: 8.661

6.  Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

Authors:  Alessandro D Santin; Stefania Bellone; Eric R Siegel; Michela Palmieri; Maria Thomas; Martin J Cannon; Helen H Kay; Juan J Roman; Alexander Burnett; Sergio Pecorelli
Journal:  Am J Obstet Gynecol       Date:  2005-03       Impact factor: 8.661

7.  Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.

Authors:  Laura J Havrilesky; Angeles Alvarez Secord; David M O'Malley; Gloria Broadwater; Victoria Bae-Jump; David E Cohn; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2009-05-15       Impact factor: 5.482

8.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:  Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino
Journal:  Gynecol Oncol       Date:  2013-02-26       Impact factor: 5.482

9.  The impact of race on outcomes of patients with early stage uterine endometrioid carcinoma.

Authors:  Mohamed A Elshaikh; Adnan R Munkarah; Jared R Robbins; Benjamin S Laser; Neil Bhatt; Chad Cogan; Farzan Siddiqui
Journal:  Gynecol Oncol       Date:  2012-10-23       Impact factor: 5.482

10.  Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.

Authors:  Matthew A Powell; David G Mutch; Janet S Rader; Thomas J Herzog; Tim Hui-Ming Huang; Paul J Goodfellow
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

View more
  9 in total

1.  Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Authors:  Ashley S Felix; David E Cohn; Theodore M Brasky; Richard Zaino; Kay Park; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Marcus E Randall; Louise A Brinton
Journal:  Am J Obstet Gynecol       Date:  2018-08-07       Impact factor: 8.661

2.  ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription.

Authors:  Yan-Yi Xiao; Li Lin; Yong-Hao Li; Hui-Ping Jiang; Li-Tong Zhu; Yuan-Run Deng; Dan Lin; Wei Chen; Cheng-Ying Zeng; Li-Jing Wang; Shao-Cheng Chen; Qing-Ping Jiang; Chun-Hua Liu; Wei-Yi Fang; Sui-Qun Guo
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

3.  Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype.

Authors:  Megan A Clarke; Susan S Devesa; Anne Hammer; Nicolas Wentzensen
Journal:  JAMA Oncol       Date:  2022-06-01       Impact factor: 33.006

Review 4.  Controversies in the Management of Early-stage Serous Endometrial Cancer.

Authors:  Alyssa Larish; Andrea Mariani; Carrie Langstraat
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

5.  Racial disparities in survival among women with endometrial cancer in an equal access system.

Authors:  Amie B Park; Kathleen M Darcy; Chunqiao Tian; Yovanni Casablanca; Jill K Schinkel; Lindsey Enewold; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu
Journal:  Gynecol Oncol       Date:  2021-07-27       Impact factor: 5.482

6.  Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer.

Authors:  Leo Y Luo; Emeline M Aviki; Anna Lee; Marisa A Kollmeier; Nadeem R Abu-Rustum; C Jillian Tsai; Kaled M Alektiar
Journal:  Gynecol Oncol       Date:  2021-02-15       Impact factor: 5.482

7.  A Novel Predictive Tool for Determining the Risk of Early Death From Stage IV Endometrial Carcinoma: A Large Cohort Study.

Authors:  Zixuan Song; Yizi Wang; Yangzi Zhou; Dandan Zhang
Journal:  Front Oncol       Date:  2020-12-14       Impact factor: 6.244

8.  Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study.

Authors:  Daniel H Saris; Anna Jo Bodurtha Smith; Colleen Brensinger; Sarah H Kim; Ashley F Haggerty; Nawar Latif; Lori Cory; Robert L Giuntoli; Mark A Morgan; Lilie L Lin; Emily M Ko
Journal:  Gynecol Oncol Rep       Date:  2022-01-06

Review 9.  Circulating Extracellular Vesicles in Gynecological Tumors: Realities and Challenges.

Authors:  Carolina Herrero; Miguel Abal; Laura Muinelo-Romay
Journal:  Front Oncol       Date:  2020-10-14       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.